5.03MMarket Cap-0.10P/E (TTM)
0.8900High0.7705Low89.47KVolume0.8490Open0.8000Pre Close72.01KTurnover1.57%Turnover RatioLossP/E (Static)6.06MShares10.790052wk High0.65P/B4.74MFloat Cap0.691152wk Low--Dividend TTM5.71MShs Float800.0000Historical High--Div YieldTTM14.94%Amplitude0.6911Historical Low0.8040Avg Price1Lot Size
NuCana Stock Forum
NuCana's Melanoma Drug Breakthrough: 75% Disease Control Rate as Losses Shrink 31%
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
7. I DO NOT give buy or sell advice
8. CH (cash on hand); AH (after hours): RTH (regular trading hours)
9. No buy pressure/momentum- No day trade.
10. Remember, some stocks may get pumped WITHOUT any catalyst this week ...
550% CTB loading 1.5 too 1.6
EDINBURGH, United Kingdom, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors (Module 1) and in combination with docetaxel for patients with lun...
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
NuCana announced initial data from its Phase 1b/2 study of NUC-3373 in combination therapies. In Module 1, combining NUC-3373 with pembrolizumab showed promising results in 12 advanced solid tumor patients, achieving a 22% objective response rate and 67% disease control rate. Notable cases included a bladder cancer patient achieving 100% target ...
No comment yet